Janice M Leung1, Kenneth N Olivier. 1. aCritical Care Medicine Department, Clinical Center bLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Although patients with cystic fibrosis (CF) face numerous infectious pathogens over the course of their lifespan, increasing attention has recently been paid to nontuberculous mycobacteria (NTM). As reported prevalence rates rise across many countries such as the United States, the ability to recognize disease caused by NTM and subsequently treat such disease has become increasingly important. This review summarizes new observations on the epidemiology of NTM in CF as well as key elements to consider during the treatment phase. RECENT FINDINGS: Although overall rates of NTM isolation appear to be increasing, particular concern has focused on the emerging predominance of Mycobacterium abscessus. New data suggest that chronic macrolide therapy now part of routine CF care has contributed to this rise; however, these have yet to be confirmed prospectively. Transmission of M. abscessus between CF patients has also now been described through the use of genome sequencing. Although the greater virulence of M. abscessus makes it a challenging species to treat, identification of the subspecies type can now determine the presence of inducible macrolide resistance, thereby helping to guide treatment. SUMMARY: Given increasing prevalence rates, clinicians should maintain a high level of suspicion for NTM as disease-causing organisms in CF, particularly for M. abscessus. New knowledge regarding this species, however, can help to tailor appropriate therapy.
PURPOSE OF REVIEW: Although patients with cystic fibrosis (CF) face numerous infectious pathogens over the course of their lifespan, increasing attention has recently been paid to nontuberculous mycobacteria (NTM). As reported prevalence rates rise across many countries such as the United States, the ability to recognize disease caused by NTM and subsequently treat such disease has become increasingly important. This review summarizes new observations on the epidemiology of NTM in CF as well as key elements to consider during the treatment phase. RECENT FINDINGS: Although overall rates of NTM isolation appear to be increasing, particular concern has focused on the emerging predominance of Mycobacterium abscessus. New data suggest that chronic macrolide therapy now part of routine CF care has contributed to this rise; however, these have yet to be confirmed prospectively. Transmission of M. abscessus between CFpatients has also now been described through the use of genome sequencing. Although the greater virulence of M. abscessus makes it a challenging species to treat, identification of the subspecies type can now determine the presence of inducible macrolide resistance, thereby helping to guide treatment. SUMMARY: Given increasing prevalence rates, clinicians should maintain a high level of suspicion for NTM as disease-causing organisms in CF, particularly for M. abscessus. New knowledge regarding this species, however, can help to tailor appropriate therapy.
Authors: M Sanguinetti; F Ardito; E Fiscarelli; M La Sorda ; P D'Argenio; G Ricciotti; G Fadda Journal: J Clin Microbiol Date: 2001-02 Impact factor: 5.948
Authors: M Rosenfeld; R L Gibson; S McNamara; J Emerson; J L Burns; R Castile; P Hiatt; K McCoy; C B Wilson; A Inglis; A Smith; T R Martin; B W Ramsey Journal: Pediatr Pulmonol Date: 2001-11
Authors: Kenneth N Olivier; David J Weber; Richard J Wallace; Ali R Faiz; Ji-Hyun Lee; Yansheng Zhang; Barbara A Brown-Elliot; Allison Handler; Rebecca W Wilson; Michael S Schechter; Lloyd J Edwards; Subha Chakraborti; Michael R Knowles Journal: Am J Respir Crit Care Med Date: 2002-11-14 Impact factor: 21.405
Authors: In Kwon Park; Amy P Hsu; Hervé Tettelin; Shamira J Shallom; Steven K Drake; Li Ding; Un-In Wu; Nick Adamo; D Rebecca Prevots; Kenneth N Olivier; Steven M Holland; Elizabeth P Sampaio; Adrian M Zelazny Journal: J Clin Microbiol Date: 2015-08-19 Impact factor: 5.948